With support from JETRO, the Company will explore global development partnerships for its LAT1 inhibitor candidate APL1101
September 28, 2026
OSAKA, Japan — Atransen Pharma Ltd. (“Atransen Pharma” or the “Company”), led by CEO Tomoyuki Asano, announced its participation in BIO-Europe 2026, taking place November 9–11, 2026, at Koelnmesse in Cologne, Germany.
Atransen Pharma has been selected for the BIO-Europe 2026 participation support program offered by the Japan External Trade Organization (JETRO). The Company’s participation in the event is supported by JETRO.
BIO-Europe connects pharmaceutical and biotechnology companies, research institutions, and investors worldwide to explore research collaborations, development partnerships, and licensing opportunities.
Atransen Pharma’s lead development candidate, APL1101, is an oral “locking” inhibitor targeting LAT1 (SLC7A5), a transporter responsible for amino acid uptake in cancer cells. LAT1 expression is elevated in various solid tumors, including non-small cell lung cancer. Preclinical studies of APL1101 have shown antitumor activity when administered alone and alongside immune checkpoint inhibitors.
During the event, Atransen Pharma will introduce its technology and development pipeline, with a focus on APL1101. Using the official partneringONE platform, the Company will engage with pharmaceutical and biotechnology companies, research institutions, and investors to explore research collaborations, co-development, licensing, and other partnerships that could support APL1101’s global development.
Organizations interested in the Company’s technology, development programs, or collaboration opportunities are invited to request a meeting through partneringONE or contact Atransen Pharma directly using the details below.
Event Overview
- Event: BIO-Europe 2026
- In-person dates: November 9–11, 2026
- Venue: Koelnmesse, Cologne, Germany
- Organizer: Informa Connect
- Participation supported by: Japan External Trade Organization (JETRO)
- Official website: BIO-Europe 2026
- JETRO announcement: Participation support program and selected companies (Japanese)
- Organizer’s partnering guide: partneringONE access and key dates
About Atransen Pharma
Atransen Pharma Ltd. is a biotechnology startup pursuing small-molecule cancer therapies directed at the amino acid transporter LAT1. Combining expertise in structural biology, pharmacology, and chemical biology, the Company seeks to create new treatment options by targeting the nutrient supply on which cancer cells depend.
About JETRO
The Japan External Trade Organization (JETRO) is a government-related organization dedicated to promoting trade and investment. Through its network in Japan and overseas, JETRO helps Japanese businesses enter international markets and supports the global expansion of startups.
Contact
Atransen Pharma Ltd. — Communications
Email: admin@atransen.com
Website: Atransen Pharma